EUVIMEDEUVIMED entdecken
Open Access

AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity

Yigang Jin, Minjie Chen, Fei Chen, Zhaofeng Gao, Xiaoping Li, Lingyu Hu, Dandan Cai, Siqi Zhao, Zhengwei Song

Aging · 2024

DOI: 10.18632/aging.206006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Aging, 2024. Verfasst von Yigang Jin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China. Hauptthemen laut MEDLINE: Kidney Neoplasms, Carcinoma, Renal Cell, Programmed Cell Death 1 Receptor, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clear cell renal cell carcinoma (ccRCC) is a common kidney cancer with subtle early symptoms, high recurrence rates, and low sensitivity to traditional treatments like radiotherapy and chemotherapy. Identifying novel therapeutic targets is critical. The expression level of adenylate kinases 7 (AK7) in ccRCC was examined by the TCGAportal and UALCAN databases. The effect of AK7 on proliferation, invasion and migration of ccRCC cell lines was evaluated by cell assay. The correlation between AK7 expression and prognosis, as well as its direct relationship with immunotherapy efficacy, was analyzed using CANCERTOOL and Kaplan-Meier plotter data. Moreover, the TISIDB database was used to study the relationship between AK7 and immune markers. The effect of overexpressed AK7 combined with PD1 monoclonal antibody on ccRCC was evaluated in animal experiments. The results showed that low level of AK7 expression was observed in ccRCC tissues. The expression of AK7 can regulate the proliferation, invasion, and migration of human ccRCC cell lines. The level of AK7 expression was associated with OS of ccRCC patients. This was potentially due to the negative connection between AK7 expression and CD8+ T cell depletion, indicating that immunotherapy might be less effective in individuals with low AK7 expression. Conversely, augmenting AK7 demonstrated an enhanced effectiveness of anti-PD1 therapy. The findings of our research strongly indicated that AK7 could serve as both a prognostic indicator and therapeutic target for patients with ccRCC. Moreover, the overexpression of AK7 combined with anti-PD1 held promising potential as a therapeutic approach for treating ccRCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Kidney NeoplasmsCarcinoma, Renal CellProgrammed Cell Death 1 ReceptorImmunotherapyHumansCell Line, TumorAnimalsMiceCell ProliferationCell MovementImmune Checkpoint InhibitorsDisease ProgressionPrognosisFemaleMaleGene Expression Regulation, NeoplasticXenograft Model Antitumor Assays

Stichwörter der Autor:innen

adenylate kinase 7anti-PD1ccRCCimmunotherapy

Substanzen

Programmed Cell Death 1 ReceptorImmune Checkpoint InhibitorsPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Urology, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
  • Department of Surgery, The Second Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.

Zitieren

APA

Jin, Y., Chen, M., Chen, F., Gao, Z., Li, X., Hu, L., Cai, D., Zhao, S., & Song, Z. (2024). AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity. Aging. https://doi.org/10.18632/aging.206006

Vancouver

Jin Y, Chen M, Chen F, Gao Z, Li X, Hu L, et al. AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity. Aging. 2024. doi:10.18632/aging.206006

BibTeX
@article{Jin2024,
  author = {Jin, Yigang and Chen, Minjie and Chen, Fei and Gao, Zhaofeng and Li, Xiaoping and Hu, Lingyu and Cai, Dandan and Zhao, Siqi and Song, Zhengwei},
  title = {AK7-deficiency reversal inhibits ccRCC progression and boosts anti-PD1 immunotherapy sensitivity},
  journal = {Aging},
  year = {2024},
  doi = {10.18632/aging.206006}
}
Kostenlos starten →